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Vaccinia virus-specific cytotoxic T-lymphocyte (CTL) clones were established from a healthy donor, who had
been immunized with vaccinia virus vaccine, by stimulation of peripheral blood lymphocytes with UV-inactivated
vaccinia virus antigen. The phenotype of all of the clones established was CD3+ CD4+ CD8- Leull-. We used
a panel of allogeneic vaccinia virus-infected B-lymphoblastoid cell lines and demonstrated that some of the clones
recognized vaccinia virus epitopes presented by human leukocyte antigen (HILA) class II molecules. Monoclonal
antibodies specific for either HLA-DP or HLA-DR determinant reduced the cytotoxicity of specific clones. The
HLA-restricted cytotoxicity of the clones is vaccinia virus specific, because vaccinia virus-infected but not
influenza virus-infected autologous target cells were lysed. Using vaccinia virus deletion mutants, we found that
some of the CTL clones recognize an epitope(s) that lies within the HindIII KF regions of the vaccinia virus
genome. These results indicate that heterogeneous CD4+ CTL clones specific for vaccinia virus are induced in
response to infection and may be important in recovery from and protection against poxvirus infections.
There is a great deal of interest in the potential use of
vaccinia virus as a vector for recombinant vaccines against
human and veterinary diseases. Despite the success of
vaccination in the eradication of smallpox and much evi-
dence that cellular immune mechanisms are essential for
virus elimination, little is known about cellular immune
responses to vaccinia virus. In addition, vaccinia virus-
specific, human leukocyte antigen (HLA)-restricted cyto-
toxic T lymphocytes (CTLs) have not been demonstrated in
humans (12, 25), although virus-specific CTLs have been
shown with many other human viruses. Studies with murine
models have demonstrated the presence of vaccinia virus-
specific CD8+ CTL responses that are major histocompati-
bility complex (MHC) class I restricted (13, 22). Studies with
different animal species have demonstrated that these virus-
specific CTL responses correlate with recovery from poxvi-
rus infection (1, 3, 5, 10) but have not assessed the potential
effector contribution of CD4+ CTLs as part of the recovery
process.
In humans, the significance of vaccinia virus-specific
cell-mediated immune responses has been demonstrated by
studies of vaccinated children who had thymic aplasia. Some
of these children died of progressive vaccinia after acciden-
tal immunization despite producing anti-vaccinia virus anti-
bodies and treatment with massive doses of vaccine immu-
noglobulin (9, 23). Individuals with profound T-cell defects
associated with Wiscott-Aldrich syndrome also developed
disseminated infection after vaccination with vaccinia virus
(14). These and other reports (7) indicate that antibody
production alone is not sufficient to protect humans from the
complications of poxvirus infection.
In an attempt to identify the nature of the cell-mediated
cytotoxic responses in humans against vaccinia virus, we
established cytotoxic T-cell clones directed against vaccinia
virus-infected cells from a vaccinia virus-immune donor.
These clones possess the CD4 surface marker and are
vaccinia virus specific and class II restricted. The clones are
* Corresponding author.
heterogeneous because they are restricted by different MHC
class II alleles and recognize different regions of vaccinia
virus. Our results support the concept that CTL-mediated
lysis of vaccinia virus-infected target cells may be significant
in restricting the spread of virus infection and in recovery
from infection with poxvirus.
MATERIALS AND METHODS
Human PBMC. Blood was obtained from a healthy donor
who had received the standard New York City Board of
Health (NYCBH) strain of vaccinia virus in smallpox vac-
cine (Dryvax; Wyeth Laboratories, Philadelphia, Pa.) 8
months earlier. Peripheral blood mononuclear cells (PBMC)
were separated by Ficoll-Hypaque density gradient centrif-
ugation method. Cells were resuspended at 2 x 107/ml in
RPMI 1640 medium containing 10% fetal calf serum FCS
(GIBCO Laboratories, Grand Island, N.Y.) and 10% di-
methyl sulfoxide (Fisher Scientific Co., Pittsburgh, Pa.) and
were cryopreserved until use.
Vaccinia viruses. The NYCBH strain of vaccinia virus and
deletion mutants of the virus used in this study were pro-
vided by Gail Mazzara and Dennis Panicali of Applied
Biotechnology, Inc. The deletion mutants were constructed
by Lendon Payne and are shown in Table 1. Seven of these
mutants were directly generated by in vivo recombination in
cells infected with wild-type (NYCBH strain) vaccinia virus
and transfected with plasmids containing altered vaccinia
virus sequences, by methods previously described (29).
vAbT213, which contains a deletion in the thymidine kinase
gene, was selected by virtue of its growth in the presence of
bromodeoxyuridine (29). The remaining six mutants in this
group contained the Eschenchia coli lacZ gene under the
direction of a poxvirus promoter inserted at the site of the
disrupted transcription unit. These mutants were selected by
virtue of the ,B-galactosidase activity (24). vAbT342 and
vAbT247-6 each arose as a result of intramolecular recom-
bination between duplicated sequences in the genomes of
recombinant viruses. vAbT342 was isolated as a small
plaque variant of vAbT33, which contains a direct duplica-
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TABLE 1. Mutant vaccinia viruses used in this study
Virus Deletion Transcription unitsa disrupted
designation size (bp) (gene identity)
vAbT213 420 J2R (thymidine kinase)
vAbT360 180 F4L (small subunit ribonucle-
otide reductase)
vAbT217 630 A56R (hemagglutinin)
vAbT33 790 M2L (30K) and KlL (29K host
range)
vAbT71 3,460 M2L (30K), KlL (29K host
range), and K3L
vAbT342 11,000 M2L (30K) through F7L
vAbT247-6 20,000 M2L (30K) through HindIII-C'
vAbT396 F7L
vAbT70 (growth factor)b
a As defined by Goebel et al. (11).
b Because these transcription units are located in the highly variable
vaccinia virus termini, their identities cannot be defined by the sequence of
Goebel et al. (11).
tion of the vaccinia virus BamF promoter separated by 11
kb. Recombination between the duplicated sequences re-
sulted in the deletion of 11-kb intervening sequence.
vAbT247-6 was generated from a recombinant virus contain-
ing a copy of the vaccinia virus p7.5 promoter inserted in the
M2L transcription unit. The inserted p7.5 promoter recom-
bined with the native p7.5 promoter at the left end of the
vaccinia virus genome, resulting in the deletion of approxi-
mately 20 kb. Deletions were verified by isolation of genomic
DNA and digestion with restriction enzymes and compari-
son with patterns of parental vaccinia virus genomic DNA.
Southern blot analysis was also performed with appropriate
DNA fragments to confirm the deletion.
Preparation of vaccinia virus antigen. CV1 cells grown in
plastic flasks (Becton Dickinson Labware, Oxnard, Calif.)
were infected with vaccinia virus at a multiplicity of infec-
tion of approximately 0.01 PFU per cell and cultured in
Eagle's minimal essential medium containing 5% FCS until
50% of the cell monolayer exhibited cytopathic effects. The
medium was almost all removed, and the cells were scraped
from the flasks with rubber cell scrapers (Costar, Cam-
bridge, Mass.), washed, resuspended in Eagle's minimal
essential medium, and subjected to three cycles of rapid
freeze-thawing. Cells were then sonicated for 2 to 3 min,
trypsinized for 40 min at 37°C, sonicated twice, and centri-
fuged at 1,600 x g for 10 min. Ajpproximately 1 ml of antigen
was obtained from each 175-cm flask of confluent CV1 cells
and was stored at -70°C. The virus preparation was later
thawed and inactivated by UV irradiation and used as the
vaccinia virus antigen. The titer by PFU assay on CV1 cells
was 6 x 108/ml, and no plaques were detected after inacti-
vation.
Induction of proliferative responses of PBMC. PBMC (2 x
105) were cultured with the vaccinia virus antigens at various
concentrations in 0.2 ml of RPMI 1640 medium containing
10% human AB serum (Hazelton Research Products, Inc.,
Lenexa, Kans.) in 96-well round-bottomed plates (Costar) at
37°C for 4 days. Cells were pulsed with 1.25 ,uCi of [3H]thy-
midine for 16 h before harvest. Cells were harvested by using
a Titertek Multiharvester (Skatron, Inc., Sterling, Va.), and
[3HJthymidine incorporation was counted in a liquid scintil-
lation counter (Packard Instrument Co., Inc., Downers
Grove, Ill.).
Establishment of vaccinia virus-specific T-cell clones using a
limiting dilution method. PBMC (2 x 107) were incubated for
2 h with UV-inactivated vaccinia virus at a final dilution of
1:10 in 0.5 ml of RPMI 1640 medium, washed once, and
resuspended at 106 cells per ml in RPMI 1640 medium
containing 10% human AB serum and supplemented with 2
mM L-glutamine, penicillin (100 U/ml), and streptomycin
(100 p,g/ml). After 11 days, some of the stimulated cells were
used as effectors in a CTL assay and the remaining cells
were restimulated by adding gamma-irradiated (3600R)
autologous PBMC that had been preincubated for 2 h with
UV-inactivated vaccinia virus antigen, and resuspended in
the medium described above plus 10% T-cell growth factor
(Cellular Products, Inc., Buffalo, N.Y.). Two weeks later,
clusters of proliferating blast cells were collected and cul-
tured at concentrations of 1 and 3 cells per well in 96-well
round-bottomed plates with 105 gamma-irradiated vaccinia
virus antigen-pulsed autologous PBMC in 0.2 ml of the same
medium. Once weekly, half of the medium was removed and
replaced with fresh medium. On day 28, clones were ex-
panded by transferring the cells in wells with positive growth
to 48-well flat-bottomed tissue culture plates (Costar) con-
taining 106 gamma-irradiated vaccinia virus antigen-pulsed
autologous PBMC in 1 ml of RPMI 1640 medium containing
10% human AB serum and 10% T-cell growth factor.
Preparation of target cells. B-lymphoblastoid cell lines
(B-LCL) were established by Epstein-Barr virus transforma-
tion of the PBMC from the vaccinia virus-immune donor
(autologous) and from MHC HLA class I- and 1I-matched or
mismatched allogeneic donors. Culture supernatant of B95-8
cells was used as an inoculum of Epstein-Barr virus. The
B95-8 cells were provided by T. Sairenji of the University of
Massachusetts Medical Center.
The B-LCL were either uninfected (control) or infected
with vaccinia viruses (wild-type strain NYCBH and mutant
viruses) at a multiplicity of infection of 10 for 12 to 16 h,
labeled with sodium [51CrJchromate (New England Nuclear,
Boston, Mass.) for 1 h, washed three times, and resuspended
at 2 x 104/ml in RPMI 1640 medium containing 10% FCS for
use as target cells in cytotoxicity assays.
Cytotoxicity assays. Chromium-labeled target cells (2 x
103) in 0.1 ml of RPMI 1640 medium containing 10% FCS
were added to each well in round-bottomed microtiter plates
(Linbro Chemical Co., Hamden, Conn.). Various concentra-
tions of effector cells in 0.1 ml of medium were added to each
well to give the described effector/target (E/T) ratios. After a
6-h incubation at 37°C, the supernatant was harvested from
each well and counted in a gamma counter. The assays were
performed in triplicate wells, and the percent specific cell
lysis was calculated by the formula 100 x (mean experimen-
tal release - mean spontaneous release)/(mean total release
- mean spontaneous release). The results of an assay were
excluded if the average spontaneous release was .30% or if
the viability prior to 'Cr labeling was <80%.
HLA typing. Most of the donor lymphocytes used in these
experiments were typed for HLA-A, HLA-B, HLA-C, and
HLA-D antigens on unfractionated PBMC by the Tissue
Typing Laboratory at the George Washington University
Medical Center. Some of the donors' lymphocytes were
typed by using their Epstein-Barr virus-transformed B-cell
lines in the Tissue Typing Laboratory at the University of
Massachusetts Medical Center.
Phenotype analysis. Anti-Leu-2 (CD8) antibody reacts with
suppressor-cytotoxic T cells (6). Anti-Leu-3 (CD4) antibody
reacts with helper-inducer T cells (6). Anti-Leu-4 (CD3)
antibody reacts with pan T cells (20). Anti-Leu-lla (CD16)
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antibody reacts with natural killer cells (26). Anti-Leu-19
antibody also reacts with natural killer cells as well as with a
subset of cytotoxic T cells that mediate non-MHC-restricted
cytotoxicity (19). Anti-Leu-2, anti-Leu-3, anti-Leu-4, anti-
Leu-lla, and anti-Leu-19 antibodies were purchased from
Becton Dickinson and Co. (Mountain View, Calif.). Clones
were stained with monoclonal antibodies (MAbs) conjugated
with fluorescein isothiocyanate by direct immunofluores-
cence methods as described earlier (18). The percentage of
antigen-positive cells was determined by using a fluores-
cence-activated cell sorter (440; Becton Dickinson and Co.).
Antibody blocking of the lysis of vaccinia virus-infected
target cells. MAbs B7/21.7, S3/4, and OKIal recognize
HLA-DP, HLA-DQ, and HLA-DR determinants, respec-
tively. MAb W6/32 recognizes a framework determinant of
HLA class I antigens. B7/21.7 and S3/4 were kindly provided
by Nancy Reinsmoen of the University of Minnesota, Min-
neapolis. OKIal and W6/32 were provided by John Sullivan
of the University of Massachusetts Medical Center. A total
of 2 x 103 51Cr-labeled target cells in 0.1 ml were incubated
for 30 min with 0.05 ml of MAbs diluted 1:20. The effector
cells were then added in 0.05 ml and incubated for 6 h. The
percent specific cell lysis was determined as described
above.
Antibody complement depletion. Anti-OKT4 (CD4) and
anti-OKT8 (CD8) antibodies (Ortho Diagnostic Systems,
Inc., Raritan, N.J.) and anti-Leullb (CD16; Becton Dickin-
son Co.) were used in antibody complement depletion ex-
periments. A total of 2 x 106 virus-stimulated PBMC were
suspended in 50 ,ul of RPMI 1640 medium containing 1%
FCS, 100 pl of antibody diluted 1:15 was added, and the
mixture was incubated at 4°C for 30 min. The cells were
washed twice in cold RPMI 1640 medium and suspended in
100 RI, to which 200 pil of rabbit complement (Cedarlane
Laboratories, Hornby, Ontario, Canada) diluted 1:3 was
added, and the resulting solution was incubated for 1 h at
37°C. The cells were then washed three times in RPMI 1640
medium and were used in cytotoxicity assays. This treat-
ment resulted in complete depletion of CD8+ and Leullb+
cells, and 80% decrease in CD4+ cells as demonstrated by
fluorescence-activated sorting.
RESULTS
Proliferative response ofPBMC to vaccinia virus antigens in
bulk culture. The immune responses to vaccinia virus anti-
gen by a healthy donor, who had been immunized 8 months
earlier with live vaccinia virus vaccine supplied by the
Centers for Disease Control, were examined by culturing
their PBMC with UV-inactivated vaccinia antigen and mea-
suring [3H]thymidine incorporation. The PBMC showed a
dose-dependent response to vaccinia virus antigen, with
maximal responses ranging from 11,000 to 30,000 cpm (data
not shown). No responses were detected when the culture
supematant of uninfected CV1 cells was used as a control
antigen.
Induction of cytotoxic effector cells against vaccinia virus-
infected autologous target cells. The donor's PBMC were
stimulated in vitro with gamma-irradiated autologous PBMC
pulsed with UV-inactivated vaccinia virus and maintained in
medium containing 10% heat-inactivated human AB serum
and 10% T-cell growth factor. After 11 days of in vitro
culture, the proliferating cells were tested for cytotoxic
activity against autologous vaccinia virus-infected B-LCL,
which had been demonstrated in preliminary experiments to
contain vaccinia virus antigens by fluorescent-antibody
a 40-
.20-
CO)
10
0
C VAC K562 VAC K562
FIG. 1. Cytotoxic activity of the in vitro culture of effector cells
against uninfected (C) or vaccinia virus-infected (VAC) autologous
B-LCL and K562 cells. (A) CTL response with E/T ratios of 50:1
(El) and 25:1 (1m ) on day 11. (B) CTL response after depletion of
the Leull population on day 21 (1) with an E/T ratio of 50:1.
Spontaneous release was 15 to 22%.
staining (data not presented). As shown in Fig. 1A, the
stimulated effector cell population exhibited significant lysis
of vaccinia virus-infected autologous targets ranging from 30
to 50% but did not kill uninfected targets (E/T ratios, 25:1
and 50:1). The level of cytotoxicity ofvaccinia virus-infected
targets was much higher than the lysis of the NK-sensitive
tumor cell line K562, which suggested that some of the killer
cells were vaccinia virus specific. In a repeat experiment
(Fig. 1B), depletion of the Leull population by treatment
with MAb and complement demonstrated that the level of
lysis of vaccinia virus-infected target cells was unaffected
while the lytic activity to K562 cells was inhibited by 50%
after such treatment.
Determination of the nature of cytotoxic effector cells.
Antibody complement depletion studies were carried out
after 22 days of in vitro culture to determine the identity of
the killer cells (Table 2). Treatment of the effector cells with
anti-CD4 and complement reduced their lytic capacity
against vaccinia virus-infected targets by 53%. Similarly,
depletion of the CD8+ population with anti-CD8 and com-
plement resulted in a 51% reduction in cytotoxicity, whereas
treatment with anti-Leullb and complement failed to induce
a reduction in the cytotoxic capacity of the effector cells.
These results indicate that the cytotoxicity of the bulk
culture cell line against vaccinia virus-infected targets re-
flected killing activity by both CD4+ and CD8+ CTLs.
Establishment of vaccinia virus-specific CD4+ T-cell clones.
We attempted to clone vaccinia virus-specific CTLs using a
TABLE 2. Characterization of cytotoxic activitya
% Specific 51Cr
release from %
Treatment target cells Inhibition
C VAC
No antibody 12.8 46.3
Complement 11.2 43.5
Anti-CD4 + complement 9.5 21.8 53
Anti-CD8 + complement 7.0 22.9 51
Anti-Leullb + complement 11.7 41.0 11
a Antibody complement depletion studies using effector cells on day 22 of in
vitro culture, with an E/T ratio of 25:1 in a 5-h assay.
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TABLE 3. Cytotoxic activity of clones generated from a vaccinia
virus-immune donor
Expt no. and % Specific 51Cr release from target cellsa
JC clone no. Uninfected VAC K562 Flu
Expt 1
1 3.0 47.7 1.1
11 -2.2 49.4 -2.1
46 -1.7 32.1 -0.8
51 -2.3 47.8 -0.6
88 1.8 24.2 0.7
31 1.9 6.8 1.2
36 1.1 0.9 1.0
Expt 2-
12 0.3 14.7 2.4
22 0 26.6 -3.2
30 3.6 39.9 6.5
33 1.4 30.5 1.2
32 14.7 NT 35.1
35 5.5 NT 15.4
DG 18.6 NT 57.2
a Abbreviations: VAC, vaccinia virus-infected cells; Flu, influenza virus-
infected cells; NT, not tested.
b Clones established by UV-inactivated vaccinia virus stimulation of PBL
from a healthy donor were tested for their ability to lyse uninfected or vaccinia
virus-infected autologous B-LCL and K562 cells at an E/T ratio of 3:1.
c Clones JC-12, JC-22, JC-30, and JC-33 were tested for their ability to lyse
uninfected, vaccinia virus-infected and influenza virus-infected autologous
B-LCL at an E/T ratio of 3:1. Influenza virus-specific clones (32, 35, and DG)
that had been established by stimulation of PBL with influenza virus (A/PCI
1/73) were included to show that influenza virus-infected autologous B-LCL,
which were not lysed by the vaccinia virus-specific clones, are susceptible to
lysis.
limiting dilution method as detailed in Materials and Meth-
ods. A total of 87 clones were generated from 384 wells, with
cloning efficiencies of 20% at 1 cell per well and 38% at 3
cells per well. Thirty-six of the clones were not cytotoxic for
vaccinia virus-infected or uninfected autologous B-LCL or
for K562 cells. The other 51 clones lysed vaccinia virus-
infected autologous B-LCL but did not lyse K562 target cells
or uninfected B-LCL. In Table 3, experiment 1 shows
representative examples of the two broad categories of
clones that were detected. Clones such as JC-1, JC-11,
JC-46, JC-51, and JC-88 selectively lysed vaccinia virus-
infected autologous B-LCL. Experiment 2 in Table 3 dem-
onstrated that vaccinia virus CTL clones such as JC-12,
JC-22, JC-30 and JC-33 did not lyse autologous B-LCL
infected with influenza virus. Several influenza virus-specific
CD4+ CTL clones that had been derived by in vitro stimu-
lation with influenza virus from the same donor (6a) are
included as a control to demonstrate that the influenza
virus-infected B-LCL were susceptible to lysis. These re-
sults therefore demonstrate that these vaccinia virus CTL
clones are virus specific, since they lyse vaccinia virus-
infected autologous B-LCL but not influenza virus-infected
autologous B-LCL.
Cell surface phenotypes of the vaccinia virus-specific CTL
clones. Phenotyping of the clones by fluorescence-activated
cell sorting analysis (data not shown) showed them all to be
CD3+ CD4+ CD8- Leull-. Of the 21 clones tested for
Leul9, 4 were positive and 17 were negative. The Leu19+
clones are JC-3, JC-9, JC-11, and JC-49.
HLA class II antigen-restricted lysis of target cells by T-cell
clones. The HLA restriction of lysis of target cells by
vaccinia virus-specific T-cell clones was examined by using
TABLE 4. Effect of anti-HLA class I and II antibodies on the
lysis of target cells by vaccinia virus-specific CTL clonesa
JC
clone
no.
% Specific '1Cr release for MAbb:
W6/32 B7/21.7 OKIal S3/4
None (anti-class I) (anti-HLA-DP) (anti-HLA-DR) (anti-HLA-DQ)
18 35.2 38.1
24 38.7 39.0
30 41.4 38.9
34 49.9 49.7
46 19.5 24.0
76 30.5 34.4
87 15.8 22.3
1 84.4 92.2
9 74.1 68.3
17 48.7 42.9
11 19.5 NT
16 19.1 NT
19 17.3 21.9
33 14.1 NT
49 29.2 37.8
58 43.2 40.0
13.7
16.2
20.1
22.4
28.9
16.9
24.4
25.2
20.9
15.0
18.3
14.4
20.8
13.2
22.6
45.7
34.6
38.7
39.5
50.2
0.8
4.1
-1.2
15.1
12.2
13.7
26.0
25.5
25.7
21.8
44.0
56.8
37.2
32.9
52.3
40.8
26.0
10.3
18.2
78.7
68.1
43.4
18.7
23.7
17.8
18.1
36.4
50.2
a 2 x 103 5"Cr-labeled target cells were incubated with 104 effector cells for
5 h in the presence of MAbs, at a final dilution of 1:80.
b Boldface type indicate significant decrease or inhibition by each antibody.
NT, not tested.
MAbs to HLA antigens. As shown in Table 4, anti-HLA
class I MAb W6/32 did not inhibit lysis of target cells by
these T-cell clones. Anti-HLA-DP MAb B7/21.7 reduced the
lysis of vaccinia virus-infected autologous B-LCL by clones
JC-18, JC-24, JC-30, and JC-34. Anti-HLA-DR MAb OKIal
inhibited the lysis of target cells by clones JC-46, JC-76, and
JC-87. Lytic activity by the other clones such as JC-1, JC-9,
and JC-17 was also reduced by this MAb and to a lesser
degree by anti-HLA-DP. With six clones, JC-11, JC-16,
JC-19, JC-33, JC-49, and JC-58, no inhibition of lysis by
these MAbs was observed. The results of these MAb block-
ing experiments demonstrate that these vaccinia virus-spe-
cific CTL clones lyse autologous B-LCL targets in an HLA
class II-restricted manner. The clones are heterogeneous in
their recognition of epitopes presented by class II molecules;
10 of the 16 clones examined are restricted in their cytolytic
activity against vaccinia virus-infected autologous target
cells by HLA-DP and HLA-DR antigens.
Cytolytic activity of T-cell clones against allogeneic target
cells infected with vaccinia virus. The vaccinia virus-specific
CTL clones were tested for lytic activity using a panel of
allogeneic B-LCL that shared two or more HLA class II
antigens in order to determine the nature of their HLA
restriction. The three clones shown in Fig. 2 demonstrated
vaccinia virus-specific lysis in the context of HLA class II
determinants. JC-87, a clone with lytic activity that was
completely blocked by an anti-HLA-DR MAb, efficiently
lysed vaccinia virus-infected allogeneic targets which shared
DR4. It failed to lyse virus-infected targets with which it did
not share DR4 (WM, UMA, and WT). Lysis by clone JC-41
was reduced by anti-HLA-DQ MAb, and this clone killed
vaccinia virus-infected targets which shared DQwl but not
target cells which did not express this allele. JC-19, a clone
that was not blocked by any of the MAbs used, lysed two
allogeneic target cells sharing DR2 and DQwl, although it
did not lyse other target cells sharing these same alleles. The
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Shared HLA Antigens
Autologous
DR2, DOwI, DQw3
DR2, DQwI
DR4, DRw53, DOwl, DQw3
DR2, DOw1, DQw3
DR4, DRw53, DRw3
Autologous
DR2, DOw1, DOw3
DR2, DOw1
DR4, DRw53, DOwl, DQw3
DR4, DRw53, DOw3
DRw53, DOw3
DR2, DOwl
.
0 5 10 15 20 25
% Specific Cytotoxicity
FIG. 2. HLA restriction patterns of vaccinia virus-specific CTL
clones. CTL clones were tested for their ability to lyse autologous
and allogeneic vaccinia virus-infected B-LCL targets matched at
specific HLA class II loci, as indicated, with an E/T ratio of 2.5:1 in
a 5-h chromium release assay. Average spontaneous lysis for these
assays was always <25%. The alleles which serve as restriction
determinants for the clones tested are indicated by underlining. The
HLA serotypes of the donors whose cells were used in these
experiments were as follows: donor JC, HLA-A3, 24; B35; Cw4;
DR2,4; DQw1,3; DRw53; donor WM, HLA-A26,32; B18,55 w6;
Cw3; DR2,8; DQw1,3; DRw52; donor UMA, HLA-A11,30; B7,35;
Cw4; DR2, w6; DQw1; DRw52; donor KR, HLA-A3,25; B18,
w6,62; Cw3; DR4,10; DQwl,3; DRw53; donor WT, HLA-A1,30;
B8,14,w6; DR2,5; DQw1,3; DRw52; donor RL, HLA-A1,28;
B14,49, w4,6; Cw7; DR4; DQw3; DRw52,53; donor IK, HLA-A24,
w33; B44; DR2,5; DQw1,3; donor DM, HLA-A2,23; B44,53, w4;
Cw4,7; DR5,7; DQw2,3; DRw52,53; and donor JK, HLA-A2,24;
B7,w62; Cw3,7; DR2; DQw1.
rest of the CTL clones failed to lyse any of the allogeneic
targets included in this panel (data not shown), which also
supports the MHC-restricted nature of the killing by these
clones.
Lysis of target cells infected with deletion mutants of
vaccinia virus. Several recombinant vaccinia viruses contain-
ing deletions mainly located at the left end of the vaccinia
virus genome, as detailed in the Materials and Methods,
were used to begin our efforts to map the regions of vaccinia
virus which contain T-cell epitopes (Table 5). Four clones,
JC-49, JC-33, JC-35, and JC-20, did not lyse target cells
infected with V342 but efficiently lysed target cells infected
with the other mutant viruses. This demonstrates that the
epitope(s) recognized by these clones reside within the
HindIII KF regions of the genome which had been deleted
from the mutant virus V342. The rest of the clones shown in
Table 5 lysed target cells infected with all of the tested
recombinant mutant vaccinia viruses, implying that epitopes
which reside elsewhere in the vaccinia virus genome are
recognized by these clones.
DISCUSSION
The present study describes CD4+ CTL clones generated
after in vitro stimulation of PBMC from a vaccinia virus-
immune donor with UV-inactivated vaccinia virus antigen.
These T-cell clones are cytotoxic; they are also virus spe-
cific, since vaccinia virus-infected but not influenza virus-
TABLE 5. Lysis of autologous B-LCL infected with deletion
mutants of vaccinia virus by CTL clonesa
Clone % Specific 51Cr release from target cells
no. VAC V71 V342 V247-6 V33 V70 V213 V217 V360 V396
49 54 59 12 54 61 54 56 49 56 58
33 13 13 -7 11 14 11 16 13 13 10
35 20 19 0 18 16 19 15 19 21 19
20 14 11 -6 13 13 12 12 12 16 12
19 16 16 15 17 12 14 11 15 18 16
60 14 11 11 14 17 13 14 16 16 12
47 14 12 12 11 16 14 12 16 14 14
34 13 10 10 13 9 12 11 11 14 13
73 20 18 15 23 19 19 14 16 18 21
41 13 NT 12 NT 15 15 12 15 11 13
76 14 NT 13 NT 13 16 14 14 12 13
a CTL clones were tested for the ability to lyse autologous B-LCL infected
with either wild-type strain NYCBH (VAC) or deletion mutants of vaccinia
virus as indicated, at an E/T ratio of 5:1.
infected autologous targets were lysed. The results show a
reduction of lysis by specific clones by MAbs directed
against either a HLA-DP, HLA-DQ, or HLA-DR framework
determinant, but not by an anti-class I MAb (W6/32). Two of
the T-cell clones exerted reproducibly strong lytic activity
towards vaccinia virus-infected allogeneic targets that
shared DR4 or DQwl. A third clone lysed target cells which
shared the DR2-associated DQwl allele, which share a tight
linkage disequilibrium (2). It is possible that in the latter
case, the cell surface restricting determinant recognized by
the CTL clone is not the DR2-associated DQwl molecule but
another product coded by genes that are in a tight linkage
disequilibrium with this class II haplotype. Taken together,
these results demonstrate that these vaccinia virus-specific
CD4+ CTL clones are HLA class II restricted. Some of the
clones exhibited a different pattern of inhibition by available
anti-HLA class II MAbs. Killing by five of the clones
appears to be restricted by both HLA-DP and HLA-DR
antigens in the MAb blocking studies. The reason for this is
not known, but there is a high degree of homology between
class II molecules (21), and the T-cell epitopes recognized by
these clones may be presented by a conserved region of
HLA-DP and HLA-DR. Cytotoxicity by seven other clones
was not inhibited by MAbs directed to class II determinants.
This has been reported earlier by other investigators (16) and
has been observed by us with dengue virus CD4+ CTL
clones (17a) and may be explained by differences between
the epitopes recognized by antibodies in HLA serological
assays versus the restriction element which presents the
virus epitope to the T-cell receptor. For instance, three of six
MAbs specific for monomorphic determinants on HLA-DR
molecules that were used in studies of DR-restricted, CD4+
influenza virus-specific CTL clones did not inhibit cytotox-
icity (16).
The killing of vaccinia virus-infected autologous B-LCL
by the T-cell clones was expected after observing cytotoxic
responses with the bulk CTL line. Cytotoxic activity was
reduced by treatment with an anti-CD4 MAb and comple-
ment and by treatment with an anti-CD8 MAb and comple-
ment, suggesting that both CD4+ and CD8+ T cells contrib-
uted to the effector activity. Despite this observation, all 21
of the cytotoxic clones that have been examined are CD4+.
This suggests that the vaccinia virus-specific CD4+ CTL
CTL Clone No. Target
JC
WM
UMA
87 KR
WT
RL
JC
WM
41 UMAKR
RL
DM
JK
JC Autologous
RL DR4, DRw53, DOw3
19 IK DR2, DOwl, DOw3
DM DRw53, DQw3
JK DR2, DOwl
WM DR2, DOwI, DQw3
KR DR4, DRW53, DOw1, DQw3
WT DR2, DOw1, DQw3
-
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may represent a large proportion of the total vaccinia virus
CTL population. Alternatively, we may have selected for
CD4+ clones by our method of cloning and stimulation of the
cells through the use of UV-inactivated antigen preparation.
We will address this point by stimulating this donor's PBMC
with live vaccinia virus and attempt to isolate CD8+ CTL
clones.
Although vaccinia virus-specific proliferative T-cell re-
sponses as well as delayed-type hypersensitivity reactions to
vaccinia virus have previously been reported (8, 27), this is
the first demonstration of vaccinia virus-specific CTL in
humans. Poxvirus-specific CTLs have been detected in other
animal models (15, 22, 28, 31) using lymph node cells or
spleen cells. The inability to detect CTL in the peripheral
blood of subhuman primates or humans reported by other
researchers (12, 25, 30) may have been due to technical
reasons.
It is known that protection and recovery from vaccinia
virus infection is T lymphocyte dependent (17). Freed et al.
(7) reported that children with Bruton's agammaglobuline-
mia did not have adverse reactions to smallpox vaccination,
suggesting that specific neutralizing antibodies are not nec-
essary for recovery from the vaccinia virus vaccine strains.
A child with progressive vaccinia was reported to have
prompt improvement and cure after adoptive transfer of
immune leukocytes and lymph node material from vaccinia
virus-immune donors after failing to respond to hyperim-
mune gamma globulin (17). Fatal disseminated vaccinia
following vaccination, despite the administration of massive
doses of vaccine immunoglobulin (9, 23) occurred in individ-
uals who produced viral antibodies but were unable to mount
a delayed hypersensitivity reaction to a variety of antigens.
In other model systems (1, 3, 5, 10), the cell-mediated
immune response also appears to be responsible for recov-
ery and protection from poxvirus infections, since an anam-
nestic response could be demonstrated upon reexposure to
the virus.
Vaccinia vaccines provided potent long-lasting protection
against smallpox. Protection correlated with resistance to
vaccinia virus challenge intradermally. The long-term nature
of the resistance to smallpox or vaccinia virus challenge may
be due to the presence of a large number of cross-reactive
memory CTLs which would become activated and rapidly
eliminate infected cells after challenge. This presents a
problem in using vaccinia virus as a vaccine vector to
express foreign genes, e.g., human immunodeficiency virus
type 1 gpl60, because earlier immunization with vaccinia
vaccine reduced antibody and cellular immune responses to
the recombinant virus vaccine (4). Similarly, it would be
expected that a repeat dose of a recombinant vaccinia
vaccine may not induce strong immune responses to the
novel antigen. Attempts to use alternate animal poxvirus
vectors to help avoid this limitation are being considered.
Definition of cross-reactive CTL epitopes on poxviruses
would be useful in this regard.
In order to understand the immune responses to vaccinia
virus in humans, it will be necessary to map the epitopes that
are recognized by human T cells. Using deletion mutants of
vaccinia virus, we have shown that the HindlIl KF regions
of the viral genome contains potential epitopes recognized
by four of the CTL clones. Additional studies are needed to
localize the epitope(s) in this region as well as the other
epitopes elsewhere in the vaccinia virus genome that are
recognized by these vaccinia virus-specific CTL clones. The
information gathered from such studies could be important
in determining which elements of the CTL response contrib-
ute to the recovery and protection from poxvirus infections
and will be useful in designing vaccinia virus vectors for use
in recombinant vaccines.
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